NFC
CGTX icon

Northeast Financial Consultants’s Cognition Therapeutics CGTX Stock Holding History

Northeast Financial Consultants’s Portfolio CGTX Stock Details CGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		$19.6K Hold
63,351
– – ﹤0.01% 298
2025
Q1 		$26.7K Buy
63,351
+38,851
+159% +$22.8K ﹤0.01% 275
2024
Q4 		$17.2K Hold
24,500
– – ﹤0.01% 286
2024
Q3 		$11.5K Hold
24,500
– – ﹤0.01% 294
2024
Q2 		$40.7K Hold
24,500
– – ﹤0.01% 269
2024
Q1 		$44.6K Hold
24,500
– – ﹤0.01% 286
2023
Q4 		$45.3K Hold
24,500
– – ﹤0.01% 277
2023
Q3 		$35.3K Hold
24,500
– – ﹤0.01% 282
2023
Q2 		$44.8K Hold
24,500
– – ﹤0.01% 284
2023
Q1 		$48.5K Hold
24,500
– – ﹤0.01% 312
2022
Q4 		$51.5K Buy
+24,500
New +$49.5K ﹤0.01% 318

Other funds holding CGTX

BCM
BIOS Capital Management Fort Worth, Texas $52.9M AUM 30.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
VC
Voss Capital Houston, Texas $1.88B AUM 1.03% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return
AFG
American Financial Group Cincinnati, Ohio $270M AUM 3.25% 1-Year Est. Return
KAS
Kestra Advisory Services Austin, Texas $26.4B AUM 21.05% 1-Year Est. Return
SPC
Sigma Planning Corp Ann Arbor, Michigan $3.6B AUM 24.57% 1-Year Est. Return

Northeast Financial Consultants's CGTX Position: Q2 2025 in Review

Northeast Financial Consultants held its Cognition Therapeutics (CGTX) position steady in Q2 2025 at 63,351 shares worth $19.6K. The position accounts for ﹤0.01% of the portfolio, ranked #298.

Northeast Financial Consultants first reported a position in CGTX in Q4 2022 and has held it in 11 quarters since. The position peaked at $51.5K in Q4 2022. 48 funds tracked by Wall St. Rank hold CGTX as of Q2 2025.

  • Northeast Financial Consultants held 63,351 shares of Cognition Therapeutics worth $19.6K as of Q2 2025.
  • Northeast Financial Consultants left its Cognition Therapeutics share count unchanged in Q2 2025.
  • Cognition Therapeutics made up ﹤0.01% of Northeast Financial Consultants's portfolio in Q2 2025, its #298 holding.
  • Northeast Financial Consultants first reported a position in Cognition Therapeutics in Q4 2022 and has held it in 11 quarters since.
  • Northeast Financial Consultants's Cognition Therapeutics position peaked at $51.5K in Q4 2022.
  • 48 funds tracked by Wall St. Rank held Cognition Therapeutics as of Q2 2025.

Based on Northeast Financial Consultants's 13F filing for Q2 2025, filed 15 Aug 2025.